Reactivation of Human Herpesvirus 6 and Epstein-Barr Virus in relapsing remitting multiple sclerosis: association with disabilities, disease progression, and inflammatory processes

Abbas F. Almulla, Aristo Vojdani, Yingqian Zhang, Elroy Vojdani, Michael MaesmedRxiv 2024 · DOI

TL;DR

This study demonstrates that the reactivation of Human Herpesvirus 6 (HHV-6) and Epstein-Barr Virus (EBV) is a primary driver of inflammation and disability in relapsing-remitting multiple sclerosis (RRMS). By measuring antibodies against viral dUTPase—a specific marker of active viral replication—researchers were able to distinguish MS patients from healthy controls with up to 97.1% accuracy using neural network models.

What Problem Does This Paper Address?

While Multiple Sclerosis (MS) is widely recognized as a chronic autoimmune disorder where the immune system attacks the central nervous system, the "trigger" for these attacks remains a subject of intense debate. Epstein-Barr Virus (EBV) and Human Herpesvirus 6 (HHV-6) have long been suspects, but previous research often relied on general antibody levels that don't necessarily indicate active viral activity.

The authors sought to bridge the gap between viral infection and clinical symptoms. Specifically, they investigated whether these viruses are actively replicating (or "reactivating") during the remitted phase of RRMS and how that activity correlates with specific inflammatory pathways, physical disability, and the overall speed of disease progression.

Methods

The researchers conducted a case-control study involving 58 RRMS patients and 60 healthy controls. Their approach combined traditional clinical assessment with advanced biochemical and computational modeling:

  • Viral Biomarkers: They used Enzyme-Linked Immunosorbent Assays (ELISA) to detect IgG, IgM, and IgA antibodies. Crucially, they targeted deoxyuridine-triphosphatase (dUTPase), a protein only expressed during active viral replication or "abortive" lytic cycles.
  • Immune Profiling: Multiplex immunoassays measured a wide array of cytokines and chemokines. These were used to calculate composite "z-scores" for specific immune profiles, such as M1 macrophage activation, Th1, and Th17 responses.
  • Clinical Scoring: Disability was measured via the Expanded Disability Status Scale (EDSS), and progression was tracked using the Multiple Sclerosis Severity Score (MSSS).
  • Machine Learning: Beyond standard regression, the team employed Multilayer Perceptron (MLP) neural networks to determine which combination of viral and immune markers best predicted an RRMS diagnosis.

Datasets

The study utilized a primary dataset of 118 participants recruited between 2021 and 2022 from the Neuroscience Center of Alsader Medical City in Al-Najaf, Iraq.

  • RRMS Group: 58 patients in the remitted phase.
  • Control Group: 60 healthy individuals (hospital staff and acquaintances) from the same demographic area.

Key Insights and Ideas

  • The "Smoking Gun" of dUTPase: Unlike standard viral antigens, dUTPase acts as a Pathogen-Associated Molecular Pattern (PAMP). Its presence suggests the virus is actively "waking up" and triggering the innate immune system via Toll-Like Receptors and NF-κB pathways.
  • The Inflammatory Bridge: The study found that viral reactivation doesn't cause disability in a vacuum. Instead, HHV-6 and EBV dUTPases appear to drive the activation of M1 macrophage and Th17 cytokine profiles, which then correlate directly with higher disability scores.
  • Viral Activity vs. Disease Duration: Interestingly, IgA responses to these viral enzymes were inversely correlated with the duration of the illness. This suggests that viral replication might actually decrease as the disease progresses over decades, potentially explaining why relapse rates often decline with age.
  • Abortive Lytic Cycles: The high IgG levels against dUTPases suggest "abortive" replication—where the virus starts to replicate and produces inflammatory proteins but doesn't necessarily complete the cycle to form new infectious virions.

Key Results

  • High Diagnostic Accuracy: Using just IgG and IgM against HHV-6 dUTPase, the researchers could discriminate RRMS patients from controls with 91.5% accuracy.
  • Neural Network Performance: When the neural network combined viral markers (EBV-dUTPase) with immune profiles, the predictive accuracy jumped to 97.1%, with an Area Under the ROC Curve (AUC) of nearly 1.0.
  • Strong Clinical Correlation: Viral markers and immune activation indices explained a massive 77.6% of the variance in EDSS (disability) scores and 64.4% of the variance in MSSS (progression) scores.
  • Significant Elevation: All nine viral antibody markers (IgG/IgA/IgM for EBNA, EBV-dUTPase, and HHV-6-dUTPase) were significantly higher in RRMS patients than in healthy controls (p < 0.0001).

Limitations and Future Work

The authors acknowledge a few key areas for further exploration:

  • Causality vs. Association: As a case-control study, it shows a strong link but cannot definitively prove that viral reactivation causes the onset of MS.
  • Oxidative Stress: While the study focused on cytokine profiles, the authors suggest that future work should integrate markers of oxidative and nitrosative stress to complete the pathophysiological picture.
  • Therapeutic Potential: The findings point toward EBV and HHV-6 dUTPases as potential new drug targets. Future research could investigate whether antiviral therapies specifically targeting these enzymes could prevent relapses or slow progression.

Summary updated

Abstract

Abstract Background Multiple sclerosis (MS) is a chronic autoimmune disorder affecting the central nervous system (CNS). Reactivation of Human herpesvirus 6 (HHV-6) and Epstein-Barr virus (EBV) is observed in MS. Objectives This study investigates immunoglobulins (Ig)G, IgM, and IgA directed against EBV nuclear antigen EBNA-366-406, HHV-6 and EBV deoxyuridine-triphosphatase (dUTPase), and different immune profiles in 58 patients with relapsing remitting MS (RRMS) compared to 60 healthy controls. Methods We employed enzyme-linked immunosorbent assays (ELISA) to measure the immunoglobulins to viral antigens. Multiplex immunoassays were used to measure cytokines, chemokines and growth factor levels that were used to compute immune profiles, including M1 macrophage, T helper (Th)-1, Th-17, and overall immune activation. We assessed disabilities using the Expanded Disability Status Scale (EDSS) and disease progression using the Multiple Sclerosis Severity Score (MSSS). Results IgG/IgA/IgM directed to the three viral antigens were significantly higher in RRMS than in controls. RRMS was significantly discriminated from controls by using IgG and IgM against HHV-6 dUTPase, yielding an accuracy of 91.5% (sensitivity=87.3% and specificity=95.2%). Neural network analysis showed that using IgG to EBV-dUTPase, IgM to EBV-dUTPase, and immune profiles yielded an area under the ROC curve of 1 and a predictive accuracy of 97.1%. There were strong associations between IgG/IgM responses to HHV-6 and EBV-dUTPases and the EDSS/MSSS scores and aberrations in M1, Th-17, profiles, and overall immune activation. Conclusions HHV-6 and EBV reactivation play a key role in RRMS and these effects are mediated by activation of cytokine profiles.
BibTeX
@misc{almulla2024reactivation,
  author = {Abbas F. Almulla and Aristo Vojdani and Yingqian Zhang and Elroy Vojdani and Michael Maes},
  title = {{Reactivation of Human Herpesvirus 6 and Epstein-Barr Virus in relapsing remitting multiple sclerosis: association with disabilities, disease progression, and inflammatory processes}},
  year = {2024},
  doi = {10.1101/2024.09.10.24313388},
  howpublished = {medRxiv},
}
Figure